55225-86-0

Basic information

• Product Name: 3-(TrifluoroMethoxy)phenyl isocyanate
• Synonyms: 3-(TrifluoroMethoxy)phenyl isocyanate;3-(TrifluoroMethoxy)phenyl isocyate
• CAS NO: 55225-86-0
• Molecular Formula: C8H4F3NO2
• Molecular Weight: 203.1180696
• Mol File: 55225-86-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(TrifluoroMethoxy)phenyl isocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(TrifluoroMethoxy)phenyl isocyanate(55225-86-0)
• EPA Substance Registry System: 3-(TrifluoroMethoxy)phenyl isocyanate(55225-86-0)

Safety Data

• Hazardous Substances Data: 55225-86-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(Trifluoromethoxy)phenyl isocyanate is used as a key intermediate for the synthesis of pharmaceutical compounds. Its unique chemical properties allow for the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(Trifluoromethoxy)phenyl isocyanate is utilized as a precursor in the production of pesticides and other agrochemicals. Its reactivity enables the creation of compounds with enhanced pesticidal properties, contributing to more effective crop protection.
Used in Advanced Materials Industry:
3-(Trifluoromethoxy)phenyl isocyanate is employed as a building block in the development of advanced materials, such as polymers and coatings. Its incorporation into these materials can impart desirable properties, including improved durability, chemical resistance, and thermal stability.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 1535-73-5 m-trifluoromethoxyaniline 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 55225-09-7 3-(trifluoromethoxy)-3',5'-bis(trifluoromethyl)carbanilide 
• 1423126-80-0 C₁₄H₁₁F₃N₂O₃ 
• 929195-04-0 C₂₃H₃₀F₃N₃O₂ 

Relevant articles and documents

Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response

Heme-regulated inhibitor (HRI), an eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, plays critical roles in cell proliferation, differentiation, adaptation to stress, and hemoglobin disorders. HRI phosphorylates eIF2α, which couples cellular signals, including endoplasmic reticulum (ER) stress, to translation. We previously identified 1,3-diarylureas and 1-((1,4-trans)-4-aryloxycyclohexyl)-3-arylureas (cHAUs) as specific activators of HRI that trigger the eIF2α phosphorylation arm of ER stress response as molecular probes for studying HRI biology and its potential as a druggable target. To develop drug-like cHAUs needed for in vivo studies, we undertook bioassay-guided structure-activity relationship studies and tested them in the surrogate eIF2α phosphorylation and cell proliferation assays. We further evaluated some of these cHAUs in endogenous eIF2α phosphorylation and in the expression of the transcription factor C/EBP homologous protein (CHOP) and its mRNA, demonstrating significantly improved solubility and/or potencies. These cHAUs are excellent candidates for lead optimization for development of investigational new drugs that potently and specifically activate HRI.

Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo

We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis using cell- and transgenic-zebrafish- based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin -4-yloxy)phenyl)-3-(4-chloro-3- (trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti-AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once-daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.